A Pulmonary Formulation of L-Dopa Enhances Its Effectiveness in a Rat Model of Parkinson’s Disease

Raymond T. Bartus, Dwaine Emerich, Pam Snodgrass-Belt, Karen Fu, Heather Salzberg-Brenhouse, Denise Lafreniere, Leah Novak, Ee-Sing Lo, Thomas Cooper, and Anthony S. Basile


Received December 15, 2003; accepted March 18, 2004

ABSTRACT

The efficacy of oral L-dopa becomes problematic with the progression of Parkinson’s disease, due in large part to a lost ability to accommodate L-dopa’s inherently poor pharmacokinetics. Pulmonary delivery represents a novel approach to reducing this problem. L-dopa was formulated into inhalable (Alkermes AIR) particles, and its pharmacokinetics and pharmacodynamics compared with those of an oral formulation. Pulmonary administration of L-dopa (2 mg) to rats resulted in a rapid elevation of plasma levels (Cmax = 4.8 ± 1.10 μg/ml at 2 min), whereas oral administration of L-dopa produced a much delayed and lower Cmax (1.8 ± 0.40 μg/ml at 30 min). In a rat model of Parkinson’s disease (unilateral 6-hydroxydopamine lesion), the pulmonary formulation of L-dopa (0.5–2.0 mg) yielded more rapid and robust elevations in striatal L-dopa, dopamine, and dihydroxyphenylacetic acid levels, as well as 2.5 to 3.7 times as many c-fos-expressing striatal neurons. Moreover, motor function was significantly improved by 10 min after administration, with peak improvements occurring within 15 to 30 min. In contrast, considerably higher doses (6.8–10 mg) of orally administered L-dopa took over three times longer to produce similar effects. These results suggest that an inhalable formulation of L-dopa has superior pharmacokinetic properties and may provide patients with a more effective form of rescue therapy as well as being a reliable adjuvant or replacement for first-line oral therapy.

More than 2.1 million people worldwide suffer from Parkinson’s disease (PD), a neurological syndrome characterized by bradykinesia, postural instability, rigidity, and involuntary tremor (Lanza and Nagle, 2002). These motor symptoms result from the progressive degeneration of dopaminergic neurons in the pars compacta of the substantia nigra, which project to the striatum (Dunnett and Bjorklund, 1999). Administration of the dopamine precursor L-dopa (Cotzias et al., 1967) combined with the dopamine decarboxylase inhibitor carbidopa (Dunner et al., 1971) helps control the neurological manifestations of PD by enhancing dopamine levels in the surviving dopaminergic neurons of the substantia nigra, thereby restoring neurotransmission.

L-dopa provides a clear therapeutic benefit for most early-stage PD patients, where the duration of its pharmacodynamic effects far exceeds its plasma half-life. This reflects the ability of dopaminergic neurons to decarboxylate L-dopa to dopamine and then store sufficient amounts of dopamine to maintain adequate motor function long after plasma L-dopa levels have fallen. This storage capacity buffers the fluctuations in plasma L-dopa levels that result from its variable oral bioavailability (Rivera-Calimlim et al., 1971; Djaldetti et al., 1996), rapid metabolism and inherently poor pharmacokinetic profile (Mouradian et al., 1988; Nutt and Holford, 1996). However, the benefits of L-dopa therapy decline as PD progresses (Barbeau, 1974; Marsden and Parkes, 1976). This decrease in the duration of responsiveness to L-dopa is related to the progressive degeneration of nigral dopaminergic neurons (Diamond et al., 1987) and the subsequent loss of dopamine buffering. The resulting decline in pharmacodynamic efficacy (“wearing-off” phenomena; Fabbrini et al., 1988) mirrors the transient pharmacokinetic profile of L-dopa, resulting in the rapid return of PD symptoms consistent with its rapid metabolism (t1/2 of ~90 min) of L-dopa (Marsden and Parkes, 1976; Nutt, 1987). As nigral neurodegeneration becomes more severe, “on-off” fluctuations in motor function, characterized by sudden, unpredictable cycling between states of overtreatment and suboptimal therapy (Mouradian et al., 1988) begin to occur more frequently.

ABBREVIATIONS: PD, Parkinson’s disease; 6-OHDA, 6-hydroxydopamine; DOPAC, dihydroxyphenylacetic acid; ANOVA, analysis of variance; CMC, carboxymethylcellulose.
Whether the patient suffers from motor fluctuations of the wearing-off or on-off variety, they often find themselves suddenly incapable of effective movement. An emerging treatment modality for dealing with the sudden loss of motor function and improved control of symptoms in patients with moderate PD is referred to as “rescue” therapy (Tolosa et al., 1994). The intent of this paradigm is to rapidly reestablish dopaminergic activity and motor function by administering an additional, nonscheduled dose of L-dopa when the patient does not respond to the scheduled dose or when its effects have worn off before the next scheduled dose. Nonetheless, significant problems with the use of oral L-dopa for rescue therapy remain, including variable gastrointestinal absorption and a relatively long time (30–45 min) before PD symptoms are controlled (Melamed et al., 1999). This delay not only results in patients suffering while waiting for the rescue dose to take effect but also may contribute to the excursions in plasma concentrations resulting in the development of serious motor complications, such as dyskinesias, sufficiently severe to require hospitalization (Olanow and Obeso, 2000).

The need for rapid rescue of patients with PD in the face of declining efficacy of L-dopa, complicated by the variable bioavailability and poor pharmacokinetics of oral formulations, have led us to develop a pulmonary formulation of L-dopa. This was accomplished using a novel pulmonary delivery technology [Advanced Inhalation Research (AIR); Alkermes, Inc., Cambridge, MA] involving the formulation of L-dopa into aerodynamic, biocompatible microparticles (Edwards et al., 1997) and their delivery deep into the lungs using a robust yet compact inhalation device (Dunbar et al., 2002). Unlike aerosols and large particles, AIR particles have aerodynamic properties that allow for their dispersal deep into the lungs, where they are deposited upon the alveolar membranes. This allows the particles to rapidly deliver the active principle into the systemic circulation. Drugs absorbed through the lungs then enter the heart via the pulmonary artery and are transported directly to the brain via the ascending aorta and carotid arteries. Thus, the pulmonary route may provide a means for the rapid and efficient delivery of L-dopa to the brain, avoiding the gut and its associated problems of erratic absorption and extensive metabolism.

The following investigations compare the pharmacokinetic, neurochemical, and behavioral characteristics of L-dopa administered using oral and pulmonary formulations delivered to a rodent model of PD. These studies demonstrate several advantages of pulmonary delivery of L-dopa over the oral route and establish the concept that an inhalable formulation of L-dopa may provide a relatively simple and effective means for improving the treatment of PD patients.

**Materials and Methods**

**Animals.** Male Sprague-Dawley rats (450 ± 50 g; Taconic Farms, Germantown, NY) were used in all studies. Rats were pair-housed in polypropylene cages with free access to food and water. The vivarium was maintained on a 12-h light/dark cycle with a room temperature of 22 ± 1°C and relative humidity level of 50 ± 5%. All studies were approved by Alkermes Institutional Animal Care and Use Committee and were conducted in adherence with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

**Preparation of Inhalable L-Dopa.** Inhalable L-dopa particles were prepared using proprietary techniques developed by AIR. L-dopa and excipients (9 g/l) were mixed into a spray drying solution with 70:30 ethanol/water (v/v) as the solvent. The solution was then introduced into a Niro spray dryer at 40 ml/min and atomized into droplets with a rotary atomizer at 20,000 rpm. The droplets contact hot gas and the droplets were collected with 0.5-inch cyclone. The final loading density of L-dopa in the particles is 20%.

**L-Dopa Pharmacokinetics.** Determinations of L-dopa plasma levels were made after oral gavage or insufflation into the lungs. Rats received an i.p. injection of the peripheral decarboxylase inhibitor carbidopa (200 mg/kg) 1 h before administration of L-dopa. Under ketamine/xylazine/acepromazine (33/1.7/10 mg/kg) anesthesia, the animals received femoral artery catheters for blood sampling and were subsequently divided into two groups. The first group of animals was orally administered L-dopa (2 mg) suspended in 1 ml of saline containing 3% carboxymethylcellulose (CMC) and 1% ascorbic acid. The second group was administered AIR-L-dopa particles (20% loading density) via pulmonary insufflation. A laryngoscope was used to visualize the rat’s epiglottis and a blunt-tip insufflator (PennCentury Insufflation Powder delivery device) inserted into the airway. A bolus (3 ml) of air from an attached syringe was used to deliver the preloaded powder from the chamber of the insufflator into the rat’s lungs. No more than a total of 10 mg of powder (2 mg L-dopa) was delivered. Blood samples (500 µl) were drawn from each animal at the femoral cannula at the following time points: 0 (immediately before L-dopa administration); 2, 5, 15, 30, 60, 120, and 240 min after L-dopa administration; and placed into heparinized tubes containing 20 µl of 1 M sodium metabisulfite. After each blood sample, an equivalent volume of isotonic saline was injected through the cannula to maintain circulating fluid volume. Plasma (200 µl) was obtained from the blood samples by centrifugation at 1000g for 15 min, and then stored at −80°C until analyzed. Striata were disrupt using a probe sonicator (10 s) in diluent containing 200 mM HClO4, 0.05% Na2S2O5, and 0.05% Na2 EDTA, centrifuged at 20,000 g for 20 min, and the supernatant retained and stored at −70°C until analysis.

**Catecholamine Quantitation.** Samples were loaded into an auto-injector (6°), and 5 to 50 µl was injected onto a Supelcosil LC-18 column (4.6 mm × 150 cm, 5-µm particle size) at 37°C. The mobile phase consisted of 0.1 M KH2PO4, 80 mM acetic acid, 0.1% Na2EDTA, 0.4% Na heptanesulfonic acid, and 1.75% acetonitrile, pH 3.1, running at a flow rate of 2 ml/min. Catecholamine peaks were determined using electrochemical detection (Coulochem II; ESA, Inc., Chelmsford, MA) (oxidation cell, +250 mV; screening cell, +75 mV100 nA; and reduction cell, −375 mV20 nA). Total running time was 40 min, with the following retention times: DA, 1.3 min; 6-OHDA, 7.3 min; dihydroxybenzylamine (internal standard), 13 min; and dopamine, 23.5 min. After running, the column was washed for 10 min, and the supernatant retained and stored at −70°C until analysis.

**c-fos Immunohistochemistry.** Sixty minutes after administration of L-dopa, 6-hydroxydopamine (6-OHDA)-lesioned rats were deeply anesthetized and transcardially perfused with 200 ml of heparinized phosphate-buffered saline, and then 500 ml of 4°C Zamboni’s fixative. The brains were removed from euthanized subjects, fixed overnight in Zamboni’s fixative, and then placed in 30% sucrose/phosphate-buffered saline for cryoprotection. Brains were frozen and cut on a sliding knife microtome at 40 µm.

Sections were first washed in a Tris-buffered saline solution with 75 mM Tris, 0.15 M NaCl, and 0.05% Tween 20. After washing, the sections were incubated for 24 h in primary antibody (1:2500, SC7202; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) (anti-c-fos, 250 µg/ml). Antigen retrieval was performed by incubation in cell permeabilization solution containing 0.1% Triton X and 3% normal goat serum. Sections were incubated for 40 min at 37°C, rinsed in Tris-buffered saline, and then incubated for 1 h in biotinylated goat anti-rabbit secondary antibody (1:200; Vector Laboratories, Burlingame, CA). After washing, the sections were incubated in a solution containing 0.3% H2O2, 2.5% nickel II sulfate, 0.05% diaminobenzidine, and 0.005% hydrogen peroxide. Control tissue was treated in the same manner minus the primary antibody, and no staining was observed. All the sections were mounted, dehydrated, and coverslipped for imaging.
The 6-OHDA-Treated Rat Model of Parkinson’s Disease: Pharmacodynamic Testing. Rats were anesthetized with ketamine/xylazine/acepromazine (33:1.7:10 mg/kg) and positioned in a stereotaxic instrument. In total, 12 μg of 6-OHDA in 6 μl of 0.9% saline/ascorbic acid (0.2 μg/μl) was unilaterally infused into the medial forebrain bundle (4.2 mm posterior and 1 mm lateral to bregma, 7.4 mm ventral to dura) at a rate of 1 μl/min, and then allowed to diffuse for 5 min before the infusion cannula was slowly retracted (Lindner et al., 1996). Beginning 2 weeks after surgery, animals were tested for apomorphine-induced rotation behavior every week for 3 weeks (Ungerstedt, 1971). For this test, animals received an i.p injection of apomorphine (0.25 mg/kg for the first test and 0.1 mg/kg for the following two tests) and were placed into a cylindrical Plexiglas bucket. Each 360° rotation was counted for 30 min, and only those animals exhibiting >200 rotations/30 min were used in behavioral testing. Twelve of 30 animals passed this objective, a priori test.

Animals passing the apomorphine challenge were subsequently tested in a series of motor function tasks known to be sensitive to nigra-striatal neurodegeneration (Schallert and Tillerson, 2000). These tests allow multiple neurological evaluations in the same animal, thus permitting each animal to be used as its own control when comparing the efficacy of pulmonary versus oral L-dopa in enhancing motor function. For drug delivery before behavioral testing, animals were briefly anesthetized using 1% isoflurane. Individual test sessions were separated by 1 week.

Placing Task. The placing task requires rats to make a directed forelimb movement in response to sensory stimuli. Rats were held so that their limbs were hanging unsupported. They were then raised to the side of a table so that their bodies were parallel to the edge of the table. Each rat received 10 consecutive trials with each forelimb and the total number of times the rat placed its forelimb on the top of the table was recorded. Before each test day, animals received an i.p. injection of the peripheral decarboxylase inhibitor carbidopa (200 mg/kg) as described above. Animals then received L-dopa orally (6.8 or 10 mg) or by inhalation (0.5, 1.0, or 2.0 mg) and were tested 15, 30, 60, and 120 min later. Throughout testing with oral and pulmonary delivery of l-dopa, each animal received every possible drug combination in a randomized manner.

Bracing Task. This test was performed using the same animals immediately after placement testing. Rats were placed on a smooth stainless steel surface and gently pushed laterally 90 cm at approximately 20 cm/s. The number of steps the rat took with the forelimb on the side in which the rat was moving was recorded. Each trial included moving the rat two times in each direction.

Akinesia Task. The akinesia test was performed immediately after the placement and bracing tasks. In this test, the subject was supported on one forelimb and allowed to move on its own. The number of steps taken with the forelimb upon which the rat was standing was recorded during separate, 30-s trials for each forelimb.

Results

L-Dopa Pharmacokinetics

Plasma levels of L-dopa were elevated faster after pulmonary delivery of L-dopa (2 mg) than after oral administration (2 mg; Fig. 1; Table 1). After insufflation, peak plasma levels (T\text{max}) of L-dopa were reached at the earliest time point measured (2 min), decreasing within 15 min of administration, then remaining significantly elevated above oral levels for over 120 min (Fig. 1; Table 1). In contrast, oral administration of L-dopa resulted in a more gradual increase in plasma L-dopa levels, peaking 15 to 30 min after administration and then decreasing gradually over the next 1 to 2 h.

The oral and pulmonary routes of L-dopa delivery had a significant impact on striatal levels of L-dopa, dopamine, and DOPAC in rats with unilateral 6-OHDA lesions (Fig. 2). Lesioned animals administered L-dopa by inhalation had significantly (>4-fold) higher L-dopa levels on both sides of the striatum 5 min after administration than rats receiving oral L-dopa (p < 0.01; Fig. 2A). Striatal L-dopa levels in rats receiving pulmonary L-dopa remained elevated by approximately 2-fold above those in orally administered rats out to 30 min. L-dopa levels on the lesioned and normal sides of the striatum were not significantly different from each other, consistent with equivalent access of L-dopa to these regions through the vasculature. In contrast to L-dopa levels, dopamine levels in the unlesioned side were significantly higher than in the lesioned side for both treatment groups. However, pulmonary delivery of L-dopa produced significantly greater dopamine levels in the striatum both ipsi- and contralateral to the lesion. Dopamine levels at 15 and 30 min after pulmonary delivery were more than 2-fold higher than after oral administration (p < 0.01; Fig. 2B). Note the time differential between the increase in striatal L-dopa and dopamine levels in the pulmonary delivery group, consistent with a temporal lag associated with the conversion of L-dopa to dopamine. Finally, DOPAC levels in the lesioned striata of the pulmonary delivery group were significantly elevated above those of the oral L-dopa-treated animals at both 15- and 30-min
time points ($p < 0.01$; Fig. 2C). This is consistent with a selective increase of approximately 2.5-fold in the turnover of dopamine released from synaptic terminals arising from neurons residing in the substantia nigra on the lesioned side following pulmonary L-dopa administration.

c-fos Expression

The number of c-fos-expressing neurons was generally higher in the striatum ipsilateral to the nigral lesion after L-dopa administration [treatment $\times$ side interaction, $F_{(3,11)} = 15.5; p < 0.05$, two-way ANOVA]. Oral administration of 2 mg of L-dopa had no significant effect on the number of c-fos-expressing neurons in the striatum on either the lesioned or unlesioned side (Figs. 3, A and B, and 4) relative to vehicle treatment. Only after the oral administration of 10 mg of L-dopa was a significant increase in the numbers of c-fos-expressing neurons observed. In contrast, the number of neurons expressing c-fos mRNA after inhalation of 2 mg of L-dopa was 5 to 30 times higher than in vehicle-treated animals and 2 to 3 times higher than the 2 mg oral L-dopa groups (Figs. 3, C and D, and 4).

Motor Function

General. Pulmonary delivery of L-dopa was well tolerated, and there were no obvious deleterious effects of delivering L-dopa directly to the lungs either acutely or over repeated sessions. All animals rapidly recovered from isoflurane anesthesia, with use of the unimpaired limb returning to preanesthesia levels in all animals in less than 10 min. No animal exhibited any distress from pulmonary L-dopa during motor testing. Although formal toxicological tests were not conducted in these studies, it is worth mentioning that in pilot studies a qualitative examination of the lungs by a trained pathologist established that delivery of the pulmonary L-dopa formulation did not produce any gross damage to the lungs. This is consistent with more formal toxicology tests performed with other AIR formulations that failed to show significant toxicological effects in several species, even with chronic administration (Alkermes, Inc., unpublished regulatory documents).

Placing Task. At baseline ($T = 0$; immediately before L-dopa), the subjects performed nearly perfectly on this task using the limb on the unlesioned side, making greater than 9/10 appropriate placements. In contrast, the animals were markedly impaired in their ability to perform the same task when using the limb on the lesioned side, making approximately one response over the 10 trials. Oral L-dopa dose dependently improved the performance of the impaired limb (Fig. 5A). At the highest dose tested (10 mg), motor performance significantly improved within 30 min ($p < 0.05$; two-way ANOVA and Tukey’s test) and peaked between 1 and 2 h after drug administration. The lower dose of oral L-dopa (6.8 mg) also improved performance slightly, with maximal effects at 60 min and stable performance thereafter. No changes were noted after administration of saline.

Performance of the placing task improved rapidly after pulmonary delivery of L-dopa (Fig. 5B). At the highest dose tested (2 mg), significant improvements occurred within 10 min, and peak benefits were reached within 15 to 30 min (as opposed to 1 to 2 h with oral administration). These effects were dose-related, with significant improvements seen using doses as low as 0.5 mg of L-dopa after 1 h. Not only did the behavioral improvements occur more rapidly after pulmo-
nary delivery of L-dopa but also markedly lower total doses were required. For example, the extent of recovery with 10 mg of L-dopa given orally was comparable with the recovery seen with 1 mg (~3 mg/kg) of L-dopa given by the pulmonary route. Accordingly, when the L-dopa doses are normalized by body weight, this represents a 10-fold difference in the dose of drug required to produce equivalent peak efficacy. Moreover, the duration of motor improvement is comparable using either delivery route.

**Bracing Task.** Rats with 6-OHDA lesions of the substantia nigra manifest a profound impairment in their ability to perform this task with the limb on the lesioned side, making approximately three responses compared with approximately seven braces with the unaffected limb. Again, oral L-dopa administration improved performance of this task in a dose-related manner (Fig. 6A), with 10 mg of L-dopa significantly improving motor performance by 30 min. Maximal effects were reached within 60 min and remained consistently elevated thereafter. A lower dose of oral L-dopa (6.8 mg) did not significantly improve performance. Vehicle administration had no effect on performance of the affected limb.

In contrast to oral L-dopa, bracing performance was rapidly improved after pulmonary administration of L-dopa (Fig. 6B). Significant improvements were seen within 10 min of delivery, with peak benefits observed within 15 to 30 min (as opposed to 30–60 min after oral administration). These effects were dose-related, with statistically significant improvements seen with 1 mg of L-dopa.

**Akinesia Task.** As was seen with the placing and bracing tests, 6-OHDA-treated rats were profoundly impaired in their ability to perform the akinesia task using the limb on the lesioned side. Although the animals made approximately 17 steps with the normal limb, they made less than one-half this number with the impaired limb (range, 0–10 steps). Oral L-dopa improved performance on this task in a dose-related manner. Administration of 10 mg of L-dopa significantly improved performance within 60 min (Fig. 7A). A lower oral dose of L-dopa (6.8 mg) produced the same pattern of recovery, although the absolute magnitude of improvement was slightly less than that seen with the higher dose of L-dopa. Treatment with saline vehicle did not affect performance.

Performance of the akinesia task was rapidly improved after pulmonary administration of L-dopa, as opposed to oral administration. Significant improvements in function were seen within 10 min of pulmonary delivery of 2 mg of L-dopa, with peak benefits observed within 15 to 30 min (Fig. 7B). These effects were dose-related, with modest, but statistically significant (p < 0.05) improvements seen after 1.0 mg (120 min).
Discussion

The current basis for effective symptomatic treatment of PD requires a sustained stimulation of striatal dopaminergic receptors as a replacement for lost dopaminergic input from neurons in the substantia nigra pars compacta (Nutt and Holford, 1996). Currently, oral administration of the dopamine precursor L-dopa, in combination with the aromatic amino acid decarboxylase inhibitor carbidopa (Dunner et al., 1971), remains an important component of the therapeutic regimen for treating PD. Nonetheless, serious fluctuations in motor response gradually develop with continued use of oral L-dopa. These fluctuations in efficacy include a decay in therapeutic effect (wearing-off phenomena), unpredictable variations (on-off phenomena), and serious motor defects (e.g., dyskinesias) correlated with high plasma L-dopa levels. These motor irregularities result from a combination of factors, including extreme fluctuations in plasma levels of L-dopa associated with the oral route of administration. The involvement of a pharmacokinetic component in the development of these motor abnormalities is indicated by their reversal after careful control of plasma L-dopa levels, either through continuous intravenous (Fabbriani et al., 1988) or intraduodenal L-dopa infusions (Sage et al., 1988; Kurth et al., 1993). The data presented in this manuscript suggest that a novel, noninvasive mechanism for delivering L-dopa through the pulmonary route may offer significant pharmacokinetic, and thus therapeutic advantages over oral L-dopa therapy for PD patients.

Insufflating rats with a formulation of aerodynamic L-dopa particles increased plasma L-dopa levels 5 times faster than an equivalent dose of orally administered L-dopa (T_{max} = 4.7 versus 24 min, respectively). In addition, the total exposure of the subjects to L-dopa is significantly higher after pulmonary than oral administration (area under the curve, 570 versus 255 μg ml^{-1} min, P = 0.01, suggesting that inhalable L-dopa has enhanced bioavailability. The impact of improved L-dopa delivery through the lungs was subse-
Pulmonary delivery of L-dopa improves the motor performance of 6-OHDA-lesioned rats more rapidly and potently than orally administered L-dopa. For the akinesia test, rats with unilateral 6-OHDA lesions were administered L-dopa either by inhaling an AIR formulation of L-dopa (0.5, 1, or 2 mg)-containing particles or by oral gavage of a suspension of L-dopa (6.8 or 10 mg) in CMC. Significant increases in placing behavior were observed beginning 60 min after the oral administration of either 6.8 or 10 mg of L-dopa relative to vehicle (A). In contrast, pulmonary delivery of 2 mg of L-dopa significantly increased the number of placements after 15 min (B). Each symbol represents the mean ± S.E.M. of data from 13 rats treated with AIR L-dopa and 12 rats treated orally. *, **, significantly different from corresponding vehicle-treated group, p < 0.05 and 0.01, respectively; a, performance values are not significantly different; unaffected limb versus 2 mg of pulmonary or 10 mg of oral L-dopa; b, performance values are not significantly different, unaffected limb versus 1 or 2 mg of pulmonary or 6.8 or 10 mg of oral L-dopa, two-way ANOVA and Tukey’s post hoc analysis.

Collectively, these data suggest that administration of L-dopa via the pulmonary route shortens the time of therapeutic onset while being minimally invasive. Thus, this pulmonary formulation may provide significant benefits for the treatment of PD, particularly as it relates to improving the reliability and efficacy of rescue therapy and potentially suppressing the development of motor irregularities linked to long-term, oral L-dopa use, as discussed below.

Rescue therapy (Tolosa et al., 1994) consists of the administration of an unscheduled oral dose of L-dopa or dopamine receptor agonist to reestablish motor function in PD patients suffering from wearing-off phenomena. The use of oral L-dopa as rescue therapy remains problematic due to variable uptake from the gut and the long interval before restoration of motor function (Melamed et al., 1999). The data provided in this manuscript suggest that a pulmonary formulation of L-dopa might overcome the most serious deficiencies associated with oral L-dopa rescue therapy. Although the plasma level of L-dopa required for successful rescue therapy is unclear, effective oral doses of L-dopa for this purpose most often range between 50 and 100 mg. Given that the bioavailability of L-dopa administered by the pulmonary route is superior to that of the oral route, a sufficient quantity of L-dopa should be deliverable through the lungs to constitute a novel and effective means of providing genuine rescue therapy, if this dose-by-route differential is maintained in humans. This could be accomplished using a robust, small inhaler containing AIR L-dopa particles that can easily be carried in a shirt pocket (Dunbar et al., 2002).

In addition to improving upon the effectiveness of rescue therapy, the present results raise the possibility that a pulmonary form of L-dopa might provide enhanced reliability...
and control in delivering l-dopa for daily, first-line therapy. A delivery modality for l-dopa that avoids the vagaries of oral absorption and gut metabolism should provide greater consistency in plasma levels, resulting in more reliable and effective treatment of PD patients.

Finally, a major limitation to the effectiveness of l-dopa is the gradual development of motor complications occurring with long-term use. Compelling evidence links the development of these complications to the chronic, pulsatile stimulation of dopamine receptors occurring with oral l-dopa administration (Olanow and Obeso, 2000). The pulsatile stimulation occurs because the short half-life of l-dopa and delayed and variable gastric emptying create wide fluctuations in plasma levels. These wide fluctuations in plasma levels are believed to initiate a cascade of events that lead to l-dopa-induced dyskinesias. First, they produce significant fluctuations in brain dopamine (especially in moderate to severe patients), which, in turn, causes pulsatile stimulation of the dopamine receptors. It has been hypothesized that the pulsatile stimulation of dopamine receptors alters postsynaptic gene transcription and protein expression, which, in turn, modifies neurotransmission patterns, leading to the emergence of dyskinesias (Mouradian and Chase, 1988). In any case, the link between variable pharmacokinetics and these motor irregularities is so compelling that delayed gastric emptying is considered a pathogenic factor in nonresponding PD patients (Djaldetti et al., 1996). A pulmonary formulation of l-dopa can improve upon the highly variable time of onset and unpredictable bioavailability associated with each dose of oral l-dopa (Cedarbaum, 1987; Nutt and Holford, 1996) by removing the vagaries of gastric absorption. Given the rapid elevation in plasma l-dopa levels observed in the present study, a pulmonary form of l-dopa might have to be administered at lower, more frequent doses throughout the day, modulating the peaks while eliminating the troughs characteristic of the oral route. If this could be accomplished in humans with pulmonary delivery of l-dopa, the debilitating dyskinesias that emerge with long-term l-dopa use might be significantly reduced and/or retarded. This concept requires further investigation in animal models of l-dopa-related dyskinesias (DiMonte et al., 2000), which may then justify further long-term testing in humans.

In summary, pulmonary delivery of l-dopa provided significant pharmacokinetic advantages over oral administration in an animal model of PD. This was manifested as a more rapid and reliable time of onset and a 3- to 5-fold dose advantage. A pulmonary formulation of l-dopa could clearly benefit patients in need of rapidly acting rescue therapy, and the dose advantage, if verified in humans, raises the possibility of delivering sufficient l-dopa via the pulmonary route to either improve upon or replace the standard, but problematic, oral form of l-dopa therapy. Finally, by avoiding problems of gastric emptying and other sources of variability characteristic of the oral route, dose-to-dose variations in plasma l-dopa levels should be tempered, possibly slowing the development of motor irregularities linked to intermittent dopamine receptor stimulation.

Acknowledgments

We acknowledge the feedback and constructive comments from Drs. J. Nutt (Oregon Health & Science University, Portland, OR) and I. Shoulson (University of Rochester, Rochester, NY) during the conceptualization of this idea and early planning stages of the experiments reported herein and Drs. J. Nutt and Warren Olanow (Mount Sinai School of Medicine, New York, NY) for helpful comments on an earlier draft of this manuscript.

References


Address correspondence to: Dr. Raymond T. Bartus, Ceregene, Inc., 9381 Judicial Dr., San Diego, CA 92121. E-mail: rbtarus@ceregene.com.